Bonum Therapeutics to Present Lead Program at AACR “We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.” March 5, 2024 Press Release
Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies “We believe that this technology has broad potential and we are excited to apply it in new areas…” Nov 15, 2022 Press Release
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche “Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…” Sep 7, 2022 Press Release
